**Partial rescheduling of certain medical marijuana categories to Schedule III occurred in April 2026 via final order from Acting Attorney General Todd Blanche, covering FDA-approved products and state-licensed medical programs, while recreational cannabis remains Schedule I.** An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with closing briefs filed in August and transcripts released in early September. The DEA’s post-hearing brief argued cannabis can no longer remain in Schedule I based on HHS/FDA scientific review and medical use data, though hearing participants largely opposed broader changes. Pending D.C. Circuit litigation challenges the April order, and the administrative law judge’s recommendation plus any final rulemaking remain outstanding. These steps, alongside the Trump administration’s December 2025 executive order directing expedited action, shape trader assessments of timelines for full rescheduling.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$809,839 Wol.
Dec 31, 2026
September 30
2%
December 31
17%
$809,839 Wol.
September 30
$660 Wol.
2%
December 31
$199,608 Wol.
17%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain medical marijuana categories to Schedule III occurred in April 2026 via final order from Acting Attorney General Todd Blanche, covering FDA-approved products and state-licensed medical programs, while recreational cannabis remains Schedule I.** An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with closing briefs filed in August and transcripts released in early September. The DEA’s post-hearing brief argued cannabis can no longer remain in Schedule I based on HHS/FDA scientific review and medical use data, though hearing participants largely opposed broader changes. Pending D.C. Circuit litigation challenges the April order, and the administrative law judge’s recommendation plus any final rulemaking remain outstanding. These steps, alongside the Trump administration’s December 2025 executive order directing expedited action, shape trader assessments of timelines for full rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Wolumen
$809,839Data zakończenia
Jan 1, 2027Rynek otwarty
Feb 7, 2026, 5:04 PM ETRozstrzygający
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain medical marijuana categories to Schedule III occurred in April 2026 via final order from Acting Attorney General Todd Blanche, covering FDA-approved products and state-licensed medical programs, while recreational cannabis remains Schedule I.** An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with closing briefs filed in August and transcripts released in early September. The DEA’s post-hearing brief argued cannabis can no longer remain in Schedule I based on HHS/FDA scientific review and medical use data, though hearing participants largely opposed broader changes. Pending D.C. Circuit litigation challenges the April order, and the administrative law judge’s recommendation plus any final rulemaking remain outstanding. These steps, alongside the Trump administration’s December 2025 executive order directing expedited action, shape trader assessments of timelines for full rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$809,839Data zakończenia
Jan 1, 2027Rynek otwarty
Feb 7, 2026, 5:04 PM ETRozstrzygający
0x65070BE91...**Partial rescheduling of certain medical marijuana categories to Schedule III occurred in April 2026 via final order from Acting Attorney General Todd Blanche, covering FDA-approved products and state-licensed medical programs, while recreational cannabis remains Schedule I.** An expedited DEA administrative hearing on broader rescheduling to Schedule III ran from June 29 to July 15, 2026, with closing briefs filed in August and transcripts released in early September. The DEA’s post-hearing brief argued cannabis can no longer remain in Schedule I based on HHS/FDA scientific review and medical use data, though hearing participants largely opposed broader changes. Pending D.C. Circuit litigation challenges the April order, and the administrative law judge’s recommendation plus any final rulemaking remain outstanding. These steps, alongside the Trump administration’s December 2025 executive order directing expedited action, shape trader assessments of timelines for full rescheduling.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania